BBI Solutions has completed the acquisition of BioTeZ Berlin-Buch—a Germany-based manufacturer of reagents and finished tests for the in-vitro diagnostics market.
BBI Solutions, an independent provider of immune-diagnostic reagents and contract services, has announced on Jan. 4, 2022 that it has completed the acquisition of BioTeZ Berlin-Buch—a Germany-based manufacturer of reagents and finished tests for the in-vitro diagnostics market.
Through the acquisition, which also includes Steffens Biotechnische Analysen, BBI Solutions will increase its capabilities and will enhance its portfolio and position as a ‘complete’ immunoassay reagent supplier. Adding to BBI Solutions’ existing portfolio will be the BioTeZ’s Streptavidin-based portfolio, as well as immunoassay development services that will complement the company’s existing service offering.
“This latest acquisition of BioTeZ and Steffens-Biotec further enhances our portfolio and positions BBI as a leading immunoassay reagent supplier,” said Mario Gualano, CEO of BBI Group in the press release. “It enables us to provide additional products and services in the fight against the COVID pandemic. The combined research and development capability will provide customers of both BioTeZ and BBI with new, innovative products and a broader portfolio for greater choice.”
“We are very proud to become part of the BBI family and to be able to reach many more customers worldwide,” added Uwe Ahnert, CEO of BioTeZ, in the press release. “In doing so, we will be able to support them in the production and development of innovative diagnostics.”
Source: BBI Solutions
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.